scholarly journals Urinary PGE-M in Men with Prostate Cancer

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4073
Author(s):  
Maeve Kiely ◽  
Ginger L. Milne ◽  
Tsion Z. Minas ◽  
Tiffany H. Dorsey ◽  
Wei Tang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Control Study ◽  
Cox Regression ◽  
Population Based ◽  
Cancer Specific Survival ◽  
The Past ◽  
All Cause Mortality ◽  
Race Ethnicity ◽  
Control Study

Urinary PGE-M is a stable metabolite of prostaglandin E2 (PGE2). PGE2 is a product of the inflammatory COX signaling pathway and has been associated with cancer incidence and metastasis. Its synthesis can be inhibited by aspirin. We investigated the association of PGE-M with lethal prostate cancer in a case–control study of African American (AA) and European American men. We measured urinary PGE-M using mass-spectrometry. Samples were obtained from 977 cases and 1022 controls at the time of recruitment. We applied multivariable logistic and Cox regression modeling to examine associations of PGE-M with prostate cancer and participant survival. Median survival follow-up was 8.4 years, with 246 deaths among cases. Self-reported aspirin use over the past 5 years was assessed with a questionnaire. Race/ethnicity was self-reported. Urinary PGE-M levels did not differ between men with prostate cancer and population-based controls. We observed no association between PGE-M and aggressive disease nor prostate-cancer-specific survival. However, we observed a statistically significant association between higher (>median) PGE-M and all-cause mortality in AA cases who did not regularly use aspirin (HR = 2.04, 95% CI 1.23–3.37). Among cases who reported using aspirin, there was no association. Our study does not support a meaningful association between urinary PGE-M and prostate cancer. Moreover, PGE-M levels were not associated with aggressive prostate cancer. However, the observed association between elevated PGE-M and all-cause mortality in AA non-aspirin users reinforces the potential benefit of aspirin to reduce mortality among AA men with prostate cancer.

535: Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer Mortality

2005 ◽  
Vol 173 (4S) ◽  
pp. 146-146
Author(s):  
Eric J. Bergstralh ◽  
Rosebud O. Roberts ◽  
Michael M. Lieber ◽  
Sara A. Farmer ◽  
Jeffrey M. Slezak ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Mortality ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Prostate Cancer Mortality ◽  
Control Study

Adherence to Mediterranean diet and prostate cancer risk in Sicily: population-based case–control study

2018 ◽  
Vol 31 (4) ◽  
pp. 269-275 ◽  
Author(s):  
Giorgio Ivan Russo ◽  
Tatiana Solinas ◽  
Daniele Urzì ◽  
Salvatore Privitera ◽  
Daniele Campisi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Mediterranean Diet ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Case Control ◽  
Control Study

Prostate cancer risk among users of finasteride and alpha-blockers – A population based case–control study

2007 ◽  
Vol 43 (4) ◽  
pp. 775-781 ◽  
Author(s):  
Teemu J. Murtola ◽  
Teuvo L.J. Tammela ◽  
Liisa Määttänen ◽  
Matti Hakama ◽  
Anssi Auvinen
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Case Control ◽  
Alpha Blockers ◽  
Control Study

Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a case–control study

EP Europace ◽  
2020 ◽  
Vol 22 (12) ◽  
pp. 1805-1811
Author(s):  
Levio Quinto ◽  
Jenniffer Cozzari ◽  
Eva Benito ◽  
Francisco Alarcón ◽  
Felipe Bisbal ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Magnetic Resonance ◽  
Case Control Study ◽  
Cox Regression ◽  
Three Dimensional ◽  
Case Control ◽  
Conventional Group ◽  
3D Navigation ◽  
Control Study

Abstract Aims Our aim was to analyse whether using delayed enhancement cardiac magnetic resonance imaging (DE-CMR) to localize veno-atrial gaps in atrial fibrillation (AF) redo ablation procedures improves outcomes during follow-up. Methods and results We conducted a case–control study with 35 consecutive patients undergoing a DE-CMR-guided Repeat-pulmonary vein isolation (Re-PVI) procedure. Those with more extensive ablations (e.g. roof lines, box) were excluded. Patients were matched for age, sex, AF pattern, and left atrial dimension with 35 patients who had undergone a conventional Re-PVI procedure guided with a three dimensional (3D)-navigation system. Procedural characteristics were recorded, and patients were followed for 24 months in a specialized outpatient clinic. The primary endpoint was freedom from recurrent AF, atrial tachycardia, or flutter. The duration of CMR-guided procedures was shorter compared to the conventional group (161 ± 52 vs. 195 ± 72 min, respectively, P = 0.049), with no significant differences in fluoroscopy or total radiofrequency time. At the 2-year follow-up, more patients in the DE-CMR-guided group remained free from recurrences compared with the conventional group (70% vs. 39%, respectively, P = 0.007). In univariate Cox-regression analyses, AF pattern [persistent AF, hazard ratio (HR) 2.66 (1.27–5.46), P = 0.006] and the use of DE-CMR [HR 0.36 (0.17–0.79), P = 0.009] predicted recurrences during follow-up; both factors remained independent predictors in multivariate analyses. Conclusion The substrate characterization provided by DE-CMR facilitates the identification of anatomical veno-atrial gaps and associates with shorter procedures and better clinical outcomes in repeated AF ablation procedures.

Association of SPARC expression with metastatic progression and prostate cancer-specific mortality after radical prostatectomy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5071-5071
Author(s):  
Claudio Jeldres ◽  
Richard Bruce Johnston ◽  
Christopher R. Porter ◽  
Peter Nelson
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cox Regression ◽  
Metastatic Progression ◽  
Rank Tests ◽  
Cancer Specific Survival ◽  
Cytoplasmic Staining ◽  
Sparc Expression ◽  
Log Rank Tests

5071 Background: We assessed the expression of the glycoprotein SPARC (secreted protein, acidic, rich in cysteine) in patients with prostate cancer (PCa) treated with radical prostatectomy (RP) and studied its association with adverse clinico-pathological features at RP and long-term clinical outcomes, such as metastatic progression after surgery and cancer-specific death. Methods: Tissues from 78 patients with PCa were used to quantify SPARC expression using tissue microarray (TMA) and immunohistochemistry techniques (IHC). Anti-SPARC mouse monoclonal antibody were use to target the protein and for each patients 4 samples of tissue were used for cytoplasmic staining. Staining of each core was reviewed by an uropathologist who assigned a score (score 0-3) to each core and a global score also assigned to each patient (score 0-3). Analyses of the data relied in cross tables, T-test analyses, survival plots and Cox regression models. Results: Higher expression of SPARC protein was recorded in patients who develop metastases during follow-up after RP (p=0.025) and in patients who died of PCa after RP (p=0.002). Median follow-up of the cohort was 9.3 years after RP. At 5 years, 95.5%, 92.0% and 89.3% of patients were metastases-free for SPARC expression score 1, 2 and 3 respectively. For the same categories, 10 years after RP, 82.2%, 77.0% and 69.9% were metastases-free (Log-rank tests all p≤0.05). Similarly, patients with high SPARC expression had worse cancer-specific survival at 5 and 10 years after RP compared to those with low SPARC expression (Log-rank tests all p≤0.01 when score 1 was compared to score 2 or score 3). Finally, advanced stage at RP (T3-T4) [p=0.04] and high Gleason sum (8-10) [p=0.02] were also associated with higher expression of SPARC. Conclusions: High SPARC expression was associated with worse outcomes in men with prostate cancer treated with radical prostatectomy. Men who developed metastatic disease and men who succumbed to prostate cancer had higher levels of SPARC at radical prostatectomy than their counterpart. SPARC may have an important role in the progression of the disease and may eventually help clinician to better ascertain the risk of progression of the disease.

Sign in / Sign up

Export Citation Format

Share Document